Market Update (NASDAQ:AMGN): Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors

[PR Newswire] – THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ — Amgen (AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment effect of adjuvant Prolia® (denosumab), . . . → Read More: Market Update (NASDAQ:AMGN): Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cancer immunotherapy Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Kite Pharma ink deal to develop cancer immunotherapies